{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T04:28:02Z","timestamp":1684470482895},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2008,9,30]],"date-time":"2008-09-30T00:00:00Z","timestamp":1222732800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1038\/ncpuro1224","type":"journal-article","created":{"date-parts":[[2008,9,30]],"date-time":"2008-09-30T07:54:26Z","timestamp":1222761266000},"page":"586-587","source":"Crossref","is-referenced-by-count":0,"title":["Are female lower urinary tract symptoms alleviated by \u03b1-adrenoreceptor antagonists?"],"prefix":"10.1038","volume":"5","author":[{"given":"Karl-Erik","family":"Andersson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,9,30]]},"reference":[{"key":"BFncpuro1224_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams P  et al. (2002) The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 21: 167\u2013178","journal-title":"Neurourol Urodyn"},{"key":"BFncpuro1224_CR2","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","volume":"50","author":"DE Irwin","year":"2006","unstructured":"Irwin DE  et al. (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50: 1306\u20131314","journal-title":"Eur Urol"},{"key":"BFncpuro1224_CR3","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1442-2042.2006.01486.x","volume":"13","author":"M Gotoh","year":"2006","unstructured":"Gotoh M  et al. (2006) Pathophysiology and subjective symptoms in women with impaired bladder emptying. Int J Urol 13: 1053\u20131057","journal-title":"Int J Urol"},{"key":"BFncpuro1224_CR4","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1097\/01.ju.0000176460.62847.23","volume":"174","author":"MR Ruggieri Sr","year":"2005","unstructured":"Ruggieri MR Sr  et al. (2005) Combined use of alpha-adrenergic and muscarinic antagonists for the treatment of voiding dysfunction. J Urol 174: 1743\u20131748","journal-title":"J Urol"},{"key":"BFncpuro1224_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/j.1464-410X.2007.07162.x","volume":"100","author":"D Robinson","year":"2007","unstructured":"Robinson D  et al. (2007) A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome. BJU Int 100: 840\u2013845","journal-title":"BJU Int"},{"key":"BFncpuro1224_CR6","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","volume":"296","author":"SA Kaplan","year":"2006","unstructured":"Kaplan SA  et al. (2006) Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296: 2319\u20132328","journal-title":"JAMA"},{"key":"BFncpuro1224_CR7","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.juro.2007.11.060","volume":"179","author":"BY Low","year":"2008","unstructured":"Low BY  et al. (2008) Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. J Urol 179: 1461\u20131469","journal-title":"J Urol"},{"key":"BFncpuro1224_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1464-410X.2006.06448.x","volume":"98","author":"K Kawabe","year":"2006","unstructured":"Kawabe K  et al. (2006) Silodosin, a new alpha1A-adrenoreceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98: 1019\u20131024","journal-title":"BJU Int"}],"container-title":["Nature Clinical Practice Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ncpuro1224","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpuro1224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ncpuro1224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T20:21:06Z","timestamp":1684441266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncpuro1224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9,30]]},"references-count":8,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["BFncpuro1224"],"URL":"https:\/\/doi.org\/10.1038\/ncpuro1224","relation":{},"ISSN":["1743-4270","1743-4289"],"issn-type":[{"value":"1743-4270","type":"print"},{"value":"1743-4289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,30]]}}}